Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kymera Therapeutics (KYMR) Income towards Parent Company: 2019-2024

Historic Income towards Parent Company for Kymera Therapeutics (KYMR) over the last 6 years, with Dec 2024 value amounting to -$261.9 million.

  • Kymera Therapeutics' Income towards Parent Company fell 28.31% to -$92.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$332.6 million, marking a year-over-year decrease of 65.94%. This contributed to the annual value of -$261.9 million for FY2024, which is 58.02% down from last year.
  • Kymera Therapeutics' Income towards Parent Company amounted to -$261.9 million in FY2024, which was down 58.02% from -$165.7 million recorded in FY2023.
  • In the past 5 years, Kymera Therapeutics' Income towards Parent Company ranged from a high of -$46.4 million in FY2020 and a low of -$261.9 million during FY2024.
  • Over the past 3 years, Kymera Therapeutics' median Income towards Parent Company value was -$165.7 million (recorded in 2023), while the average stood at -$196.3 million.
  • Data for Kymera Therapeutics' Income towards Parent Company shows a maximum YoY slumped of 116.95% (in 2021) over the last 5 years.
  • Over the past 5 years, Kymera Therapeutics' Income towards Parent Company (Yearly) stood at -$46.4 million in 2020, then plummeted by 116.95% to -$100.7 million in 2021, then plummeted by 60.30% to -$161.4 million in 2022, then declined by 2.66% to -$165.7 million in 2023, then plummeted by 58.02% to -$261.9 million in 2024.